None are FDA-approved for psoriasis and none have robust human trials
Drug-specific variables that may affect half-life Drug formulation (ie, modified or controlled release preparations extend half-life) How the drug behaves in the body (ie, zero-order, first-order, or multi-compartmental pharmacokinetics) How the drug is administered (half-life may be different with IV administration, compared to intranasal or oral administration) How the drug is cleared from the body (eg, kidneys, liver, lungs) If the drug accumulates in fat or other types of tissue If the drug binds to proteins or not Presence of metabolites or other drugs that may interact Properties of the drug, including molecule size, charge, and pKa The volume of distribution of a drug Other variables, such as if the drug is actively transported, is self-induced, or has saturation pharmacokinetics
Psychol Med 2004
Initially investigated for its potential effects on digestive tissue, researchers soon noticed possible activity in other areas of healing biology, including: Connective tissue repair Tendon and ligament healing Muscle recovery Blood vessel formation Inflammatory signaling Gastrointestinal integrity Rather than acting through a single mechanism, researchers believe BPC-157 may interact with multiple pathways involved in tissue repair and regeneration
In other words, it is not a synthetic invention so much as a naturally occurring signaling molecule that researchers have tried to understand and, in places, to study therapeutically
If one part of the network is under-supported, the entire network slows